NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05984927 |
Recruitment Status :
Recruiting
First Posted : August 9, 2023
Last Update Posted : May 1, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Age-Related Macular Degeneration | Genetic: NG101 AAV gene therapy | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 18 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | Dose Escalation Study with 3 dose cohorts |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2a Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration |
Actual Study Start Date : | September 8, 2023 |
Estimated Primary Completion Date : | January 2025 |
Estimated Study Completion Date : | January 2030 |
Arm | Intervention/treatment |
---|---|
Experimental: NG101 Gene Therapy Group 1
Single subretinal injection of 1x10^9 vector genomes of NG101 AAV gene therapy
|
Genetic: NG101 AAV gene therapy
Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector
Other Name: NG101 |
Experimental: NG101 Gene Therapy Group 2
Single subretinal injection of 3x10^9 vector genomes of NG101 AAV gene therapy
|
Genetic: NG101 AAV gene therapy
Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector
Other Name: NG101 |
Experimental: NG101 Gene Therapy Group 3
Single subretinal injection of 8x10^9 vector genomes of NG101 AAV gene therapy
|
Genetic: NG101 AAV gene therapy
Sub retinal injection of NG101 (a non-replicating adeno-associated virus serotype 8 (AAV8) vector
Other Name: NG101 |
- Adverse Events [ Time Frame: From Day 0 (pre-treatment) through Week 24 ]Incidence and severity of ocular and non-ocular adverse events (AEs) for each cohort
- Ocular and Non -Ocular Adverse Events after week 24 [ Time Frame: From Day 0 (pre-treatment) and through Weeks 52, 104, 156, 208 and 260 ]Incidence and severity of ocular and non-ocular AEs after Week 24 to Week 260 for each cohort
- Systemic Immunogenic Response [ Time Frame: From Day 0 to Weeks 12, 24, 52, and 104 ]Change in concentration of expressed aflibercept protein in vitreous samples
- Systemic Immunogenic Response [ Time Frame: From Day -7 to Weeks 4, 12, and 104 ]Change in concentration of expressed aflibercept protein in serum samples
- Systemic Immunogenic Response [ Time Frame: From Day -7 to Week 4, and week 12 if week 4 result was positive ]Change in AAV vector (NG101) genome copies as measured by qPCR in blood samples
- Systemic Immunogenic Response [ Time Frame: From Day -7 to Weeks 4, 8, 12, 24, 52, and week 104 ]Change in concentration of Anti-NG101 Transgene protein antibodies, Anti-AAV8 Neutralizing antibodies, and Anti-AAV8 Antibodies in serum samples
- Signs of CNV Activity [ Time Frame: From Day -30 to Weeks 8, 24, 52, and 104 ]Change of 1 or more signs of CNV activity assessed by Optical coherence tomography
- Central Retinal Thickness (CRT) [ Time Frame: From Screening to Weeks 24, 52, 104, 156, 208, and 260 ]Change in CRT assessed with OCT
- Best Corrected Visual Acuity (BCVA) [ Time Frame: From Screening to Weeks24, 52, 104, 156, 208 and 260 ]Change in BCVA assessed with Early Treatment Diabetic Retinopathy Study (ETDRS) scale
- Cumulative Number of Rescue Therapy Injections [ Time Frame: From Week 24 to Weeks 52, 104, 156, 208, and 260 ]The cumulative number of rescue therapy injections per subject to maintain CNV control
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years to 89 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects ≥ 50 and ≤ 89 years of age with a diagnosis of active subfoveal CNV secondary to wAMD in the Study Eye
- BCVA between 20/63 and 20/400 in the Study Eye, with BCVA decrement primarily attributable to wAMD
- Administration of at least 3 anti-VEGF injections in potential study eye in the past 6 months, the most recent of which was within 2 months prior to Screening.
- Must be pseudo phakic (status post cataract surgery) in the Study Eye
- Female subjects must be either: (1) of non-childbearing potential; or (2) of childbearing potential and using an acceptable method of birth control with a negative pregnancy test. Male subjects agree to refrain from sperm donations and practice contraception to avoid any pregnancy for 3 months after.
- Normal blood pressure (BP) and heart rate (HR), or near normal BP and HR not considered clinically significant (NCS) by the Investigator at the Screening Visits (Day -30 to Day -8 and Day -7) after 10 minutes resting in supine or sitting position
- Willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to the performance of any study-related procedures
- Willingness and ability to comply with schedule for follow-up visits and postoperative evaluations
Exclusion Criteria:
- CNV or macular edema in the Study Eye secondary to any causes other than AMD
- Any condition preventing visual acuity improvement in the Study Eye, e.g., fibrosis, atrophy, or retinal pigment epithelial tear in the center of the macula
- Any ophthalmic condition that precludes adequate ophthalmic examination or requires treatment
- Retinal detachment or history of retinal detachment in the Study Eye
- Active uncontrolled glaucoma with intraocular pressure (IOP) ≥ 30 mmHg despite treatment with more than 2 glaucoma medications, advanced glaucoma with cup-to-disc ratio of ≥ 0.9, visual field defects secondary to glaucoma that involve the macula, and/or optic atrophy from glaucoma
- History of intravitreal therapy in the Study Eye, such as intravitreal steroid injection or an investigational product, other than anti-VEGF therapy, in the 6 months prior to Screening
- History of vitrectomy, trabeculectomy, glaucoma tube-shunt procedure, minimally invasive glaucoma surgery (MIGS) device, or other filtration surgery in the Study Eye
- Any prior treatment with photodynamic therapy or retinal laser for the treatment of wAMD
- Any prior therapeutic radiation in the region of the Study Eye such as whole brain radiation, proton beam radiation, gamma knife treatment, or plaque brachytherapy
- Any previous intraocular or refractive surgery on the Study Eye within 6 months
- Any previous gene therapy in the Study Eye
- Presence of an ocular implant in the Study Eye at Screening, excluding intraocular lens and custom flex iris prosthesis
- Any diabetic retinopathy or other retinal vascular disease including retinal vein occlusion, retinal artery occlusion, retinal arterial macro aneurysm, ocular ischemic syndrome, retinal vasculitis, vitritis, posterior uveitis
- Any medically uncontrolled diabetes, defined as HbA1C > 8.0
- History of ocular melanoma
- History of any known inherited retinal disease
- Currently taking any anticoagulant therapy, which is deemed medically necessary and cannot be permanently stopped at least 2 weeks prior to NG101 injection, excluding prophylactic low-dose aspirin therapy
- Any underlying systemic diseases as unstable or severe cardiovascular, cerebrovascular, dementia or neurodegenerative diseases of a level that prevents adequate evaluation of the subject during the study, active malignancy or currently undergoing treatment for active malignancy at Screening or a history of malignancy that precludes completion of this 260 week study, and immunocompromised conditions and/or need for immunosuppressive therapy.
- Active hepatitis B or C
- History of human immunodeficiency virus (HIV), active tuberculosis, and/or syphilis
- Any significant illness that would preclude study compliance and follow-up
- Subjects who, in the Investigator's opinion, lack the mental capacity to provide written informed consent for study participation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05984927
Contact: Sheila Yi | 770-296-7301 | wetamd@neuraclegen.com | |
Contact: Hea Reung Park | wetamd@neuraclegen.com |
Canada, British Columbia | |
Vancouver Coastal Health Research Institute | Recruiting |
Vancouver, British Columbia, Canada, V5Z 3N9 | |
Contact: Levina Ira 604-875-4111 ext 62178 levina.ira@vch.ca | |
Contact: Namita Ramdin 604-875-4111 ext 69487 namita.ramdin@vch.ca | |
Principal Investigator: Eduardo Navajas, MD | |
Canada, Ontario | |
Sunnybrook Ophthalmology and Vision Services | Recruiting |
Toronto, Ontario, Canada, M4N 3M5 | |
Contact: Cindy Rutz (416) 480-5091 Cindy.Rutz@sunnybrook.ca | |
Principal Investigator: Peter Kertes, MD | |
Vitreous Retina Macula Specialists of Toronto | Recruiting |
Toronto, Ontario, Canada, M8X 2X3 | |
Contact: Tatjana Sukovic tatjana@vrmto.com | |
Principal Investigator: Netan Choudhry, MD |
Principal Investigator: | Christopher D Riemann, MD | Neuracle Genetics, Inc. Medical Director |
Responsible Party: | Neuracle Genetics, Inc |
ClinicalTrials.gov Identifier: | NCT05984927 |
Other Study ID Numbers: |
NG101WA-01 |
First Posted: | August 9, 2023 Key Record Dates |
Last Update Posted: | May 1, 2024 |
Last Verified: | April 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Wet macular degeneration |
Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases |